AI
Wednesday, August 31, 2022 11:14:16 PM
I appreciate the feedback IkeEsq. But, I will keep my list the same as it is. You are free to make your own list, and/or disagree with my list. I am ok with that.
Also, I see you have an issue with the term “clinical significance”. I will agree to go with what was directly stated during the May 10th presentation:
”Patients treated with DCVax-L showed a clinically meaningful and statistically significant extension of survival in both newly diagnosed and recurrent GBM, with an excellent safety profile, and noteworthy long tails of survival.”
Also, I see you have an issue with the term “clinical significance”. I will agree to go with what was directly stated during the May 10th presentation:
”Patients treated with DCVax-L showed a clinically meaningful and statistically significant extension of survival in both newly diagnosed and recurrent GBM, with an excellent safety profile, and noteworthy long tails of survival.”
